Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Calidi Biotherapeutics Inc's Business Segments
Calidi Biotherapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Member
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Member0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Member | - | - |
Description of Calidi Biotherapeutics Inc
Calidi Biotherapeutics Inc is a clinical-stage biotechnology company that specializes in developing cell-based therapies for the treatment of cancer. The company is headquartered in San Diego, California, and was founded in 2016.
Calidi Biotherapeutics focuses on utilizing its proprietary cell-based therapy platform, known as the 3-Vec system, to engineer and manufacture off-the-shelf, allogeneic Multi-Modal Oncolytic Virus-based cellular immunotherapies. These therapies are designed to target and destroy cancer cells while simultaneously stimulating the patient's immune system to mount an effective anti-tumor response.
The company's 3-Vec system allows for the generation of highly potent viruses that selectively replicate and infect cancer cells, leading to their destruction. These viruses are engineered to express various therapeutic payloads, such as immune modulators, oncolytic agents, and other anti-cancer agents. Additionally, the 3-Vec system enables the simultaneous expression of multiple therapeutic agents within a single virus, enhancing the potential effectiveness of the treatment.
Calidi Biotherapeutics' Multi-Modal Oncolytic Virus-based therapies have shown promising results in preclinical studies, displaying potent anti-tumor activity and prolonged survival rates in various cancer models. The therapies have also demonstrated the ability to stimulate strong and durable immune responses, which may improve long-term patient outcomes.
The company's pipeline includes several product candidates, including CalidiVax, which is a Multi-Modal Oncolytic Virus-based therapy being developed for the treatment of solid tumors. CalidiVax has the potential to be administered intravenously, making it easily accessible and suitable for a wide range of cancer patients.
In addition to its cell-based therapy platform, Calidi Biotherapeutics also utilizes state-of-the-art manufacturing capabilities to produce clinical-grade viral vectors and cell-based therapies. The company's experienced team of scientists, engineers, and clinicians work closely together to advance novel therapies from the preclinical stage through clinical development and regulatory approval.
Overall, Calidi Biotherapeutics Inc is at the forefront of developing cutting-edge cell-based therapies that have the potential to revolutionize cancer treatment. Through its innovative 3-Vec system and robust pipeline, the company aims to provide effective and accessible therapies to patients suffering from various types of cancer.
Calidi Biotherapeutics focuses on utilizing its proprietary cell-based therapy platform, known as the 3-Vec system, to engineer and manufacture off-the-shelf, allogeneic Multi-Modal Oncolytic Virus-based cellular immunotherapies. These therapies are designed to target and destroy cancer cells while simultaneously stimulating the patient's immune system to mount an effective anti-tumor response.
The company's 3-Vec system allows for the generation of highly potent viruses that selectively replicate and infect cancer cells, leading to their destruction. These viruses are engineered to express various therapeutic payloads, such as immune modulators, oncolytic agents, and other anti-cancer agents. Additionally, the 3-Vec system enables the simultaneous expression of multiple therapeutic agents within a single virus, enhancing the potential effectiveness of the treatment.
Calidi Biotherapeutics' Multi-Modal Oncolytic Virus-based therapies have shown promising results in preclinical studies, displaying potent anti-tumor activity and prolonged survival rates in various cancer models. The therapies have also demonstrated the ability to stimulate strong and durable immune responses, which may improve long-term patient outcomes.
The company's pipeline includes several product candidates, including CalidiVax, which is a Multi-Modal Oncolytic Virus-based therapy being developed for the treatment of solid tumors. CalidiVax has the potential to be administered intravenously, making it easily accessible and suitable for a wide range of cancer patients.
In addition to its cell-based therapy platform, Calidi Biotherapeutics also utilizes state-of-the-art manufacturing capabilities to produce clinical-grade viral vectors and cell-based therapies. The company's experienced team of scientists, engineers, and clinicians work closely together to advance novel therapies from the preclinical stage through clinical development and regulatory approval.
Overall, Calidi Biotherapeutics Inc is at the forefront of developing cutting-edge cell-based therapies that have the potential to revolutionize cancer treatment. Through its innovative 3-Vec system and robust pipeline, the company aims to provide effective and accessible therapies to patients suffering from various types of cancer.
Calidi Biotherapeutics Inc. is a pioneering biotechnology firm that specializes in oncolytic virus-based immunotherapies, targeting cancer treatment with innovative approaches designed to enhance patient outcomes. The company’s offerings can be categorized into distinct segments, encompassing research and development, products, and comprehensive services.
Segments:
1. Research and Development (R&D):
Calidi Biotherapeutics is committed to extensive research and development efforts, emphasizing innovation in oncolytic viruses. This segment focuses on several key areas:
- Discovery of New Therapies: The R&D team conducts rigorous studies to identify and develop novel oncolytic virus therapies that can effectively target various cancer types.
- Improvement of Existing Treatments: Continuous evaluation and optimization of current treatment protocols are undertaken to enhance their efficacy and safety profiles.
- Pipeline Expansion: The company is dedicated to broadening its pipeline, exploring different cancer indications and treatment modalities to address unmet medical needs in oncology.
Products:
1. Oncolytic Virus Therapies:
- Calidi Biotherapeutics utilizes its proprietary CRAd (Conditionally Replicative Adenovirus) platform technology to create innovative oncolytic virus treatments. These therapies are engineered to selectively infect and lyse cancer cells, thereby sparing normal, healthy cells. This selective targeting is designed to minimize side effects commonly associated with traditional cancer therapies, such as chemotherapy and radiation.
2. Calidi’s CLTX-CD19 CAR-T:
- This innovative product represents a convergence of CAR-T therapy and oncolytic virus technology. CLTX-CD19 CAR-T cells are specifically designed to target CD19-expressing cancer cells, such as those found in certain types of leukemias and lymphomas. By leveraging CRAd technology, Calidi enhances the delivery of CAR-T cells directly to the tumor environment, thereby improving their therapeutic effectiveness and reducing off-target effects.
Services:
1. Clinical Trials:
Calidi Biotherapeutics plays a crucial role in the clinical development of its oncolytic virus-based therapies. The services offered in this segment include:
- Trial Design and Planning: Expertise in designing clinical trials that align with regulatory requirements and scientific rigor ensures the robust evaluation of therapy efficacy and safety.
- Execution of Clinical Studies: Collaborating with leading medical centers, hospitals, and academic institutions for clinical study execution helps validate the companys therapies through rigorous scientific evaluation.
2. Contract Manufacturing:
The company offers state-of-the-art contract manufacturing services specializing in cellular and gene therapies. Key aspects include:
- Production Capabilities: A facility equipped with advanced technology allows for the production of clinical-grade oncolytic virus therapies, ensuring compliance with stringent manufacturing practices.
- Development Support: Calidi assists clients with the development and scaling of their therapeutic products, catering to a variety of partners including biotech firms, pharmaceutical companies, and academic research institutions.
3. Collaboration and Partnerships:
Recognizing the importance of collaboration in advancing cancer therapies, Calidi actively seeks partnerships with:
- Pharmaceutical Companies: Joint ventures may involve co-development efforts, pooling resources and expertise to expedite the development of promising treatments.
- Academic Institutions: Collaborations often include shared research initiatives, allowing for the exploration of novel applications of oncolytic virus technology.
- Commercial Entities: Establishing relationships with other commercial stakeholders enhances the potential for broader market access and distribution of therapies.
Summary:
In summary, Calidi Biotherapeutics Inc. is at the forefront of developing oncolytic virus-based immunotherapies, exemplified by its proprietary CRAd technology and the innovative CLTX-CD19 CAR-T therapy. The company’s commitment to advancing cancer treatment is evident through its dedicated R&D, diverse product offerings, and comprehensive services including clinical trial support, contract manufacturing, and strategic collaborations. By focusing on these segments, Calidi aims to improve patient outcomes and address the evolving challenges in oncological care.
Segments:
1. Research and Development (R&D):
Calidi Biotherapeutics is committed to extensive research and development efforts, emphasizing innovation in oncolytic viruses. This segment focuses on several key areas:
- Discovery of New Therapies: The R&D team conducts rigorous studies to identify and develop novel oncolytic virus therapies that can effectively target various cancer types.
- Improvement of Existing Treatments: Continuous evaluation and optimization of current treatment protocols are undertaken to enhance their efficacy and safety profiles.
- Pipeline Expansion: The company is dedicated to broadening its pipeline, exploring different cancer indications and treatment modalities to address unmet medical needs in oncology.
Products:
1. Oncolytic Virus Therapies:
- Calidi Biotherapeutics utilizes its proprietary CRAd (Conditionally Replicative Adenovirus) platform technology to create innovative oncolytic virus treatments. These therapies are engineered to selectively infect and lyse cancer cells, thereby sparing normal, healthy cells. This selective targeting is designed to minimize side effects commonly associated with traditional cancer therapies, such as chemotherapy and radiation.
2. Calidi’s CLTX-CD19 CAR-T:
- This innovative product represents a convergence of CAR-T therapy and oncolytic virus technology. CLTX-CD19 CAR-T cells are specifically designed to target CD19-expressing cancer cells, such as those found in certain types of leukemias and lymphomas. By leveraging CRAd technology, Calidi enhances the delivery of CAR-T cells directly to the tumor environment, thereby improving their therapeutic effectiveness and reducing off-target effects.
Services:
1. Clinical Trials:
Calidi Biotherapeutics plays a crucial role in the clinical development of its oncolytic virus-based therapies. The services offered in this segment include:
- Trial Design and Planning: Expertise in designing clinical trials that align with regulatory requirements and scientific rigor ensures the robust evaluation of therapy efficacy and safety.
- Execution of Clinical Studies: Collaborating with leading medical centers, hospitals, and academic institutions for clinical study execution helps validate the companys therapies through rigorous scientific evaluation.
2. Contract Manufacturing:
The company offers state-of-the-art contract manufacturing services specializing in cellular and gene therapies. Key aspects include:
- Production Capabilities: A facility equipped with advanced technology allows for the production of clinical-grade oncolytic virus therapies, ensuring compliance with stringent manufacturing practices.
- Development Support: Calidi assists clients with the development and scaling of their therapeutic products, catering to a variety of partners including biotech firms, pharmaceutical companies, and academic research institutions.
3. Collaboration and Partnerships:
Recognizing the importance of collaboration in advancing cancer therapies, Calidi actively seeks partnerships with:
- Pharmaceutical Companies: Joint ventures may involve co-development efforts, pooling resources and expertise to expedite the development of promising treatments.
- Academic Institutions: Collaborations often include shared research initiatives, allowing for the exploration of novel applications of oncolytic virus technology.
- Commercial Entities: Establishing relationships with other commercial stakeholders enhances the potential for broader market access and distribution of therapies.
Summary:
In summary, Calidi Biotherapeutics Inc. is at the forefront of developing oncolytic virus-based immunotherapies, exemplified by its proprietary CRAd technology and the innovative CLTX-CD19 CAR-T therapy. The company’s commitment to advancing cancer treatment is evident through its dedicated R&D, diverse product offerings, and comprehensive services including clinical trial support, contract manufacturing, and strategic collaborations. By focusing on these segments, Calidi aims to improve patient outcomes and address the evolving challenges in oncological care.